this page only  
Join BIO  
Member Directory  
Contact BIO  

Biotechnology Industry Organization
BIO Membership
BIO Membership Benefits


Tuesday, September 02, 2014

International | Health Care

overviewfood & agriculture
intellectual propertybio international convention
health carebio international leader award
climate & sustainabilityinternational investor & partnering meetings



Scientific American Worldview: A Global Biotechnology Perspective

An annual global biotech survey conducted by Scientific American to highlighting factors promoting and impeding biotech innovation on a country-by-country basis.


Biotech Now Podcast

There are more than 250 biologic medicines and vaccines that benefit millions of patients worldwide. In addition, there are more than 1,200 biotech diagnostic tests being used in clinics around the world. More than 600 new biologic medicines are in development, including treatments for cancer, HIV/AIDS, Alzheimerís disease, and numerous rare conditions.

Global Health
Infectious diseases are the second leading cause of death worldwide, and new infectious diseases continue to emerge. Infants and children are among the most susceptible.

Fortunately, biotech is improving the odds for millions of patients around the world with life-threatening conditions and helping to combat everyday threats confronting the developing world.
Read more

WHO: BIO | BIO Suggests Update to WHO's Naming Policy for Biological Products
BIO presentes its recommendations to the World Health Organization (WHO) to assign a distinct nonproprietary name to each unique biological product, including follow-on biologics ("biosimilars").
Read the news release

Clinical Trials: Review of the Declaration of Helsinki
BIOís comments on the World Medical Associationís (WMAís) Declaration of Helsinki.
Read BIOís comments (56 KB PDF)

Clinical Trials: ICTRP guidelines
BIO urges the ICTRP to focus on developing a procedure that would address the need to balance the incentive to innovate with the need to provide patients and health care providers with the information they need in order to assess the availability and suitability of a clinical trial.
Read the letter (116 KB PDF)




contact us | terms of use | privacy policy
© 2010 | Biotechnology Industry Organization | 1201 Maryland Ave., SW, Ste. 900 | Washington, D.C. 20024